SAXAGLIPTIN / DAPAGLIFLOZIN (Qtern®) FOR THE TREATMENT OF TYPE 2 DIABETES MELLITUS
NOT RECOMMENDED FOR PRESCRIBING (DOUBLE RED)

<table>
<thead>
<tr>
<th>Name: generic (trade)</th>
<th>What it is</th>
<th>Indication</th>
<th>Decision last revised</th>
<th>Decision Status</th>
<th>NICE / SMC Guidance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saxagliptin / dapagliflozin (Qtern®)</td>
<td>fixed dose combination of saxagliptin and dapagliflozin</td>
<td>Treatment of type 2 diabetes mellitus (T2DM) in adults</td>
<td>December 2017</td>
<td>Final</td>
<td>NICE - No Guidance SMC – accepted for restricted use</td>
</tr>
</tbody>
</table>

**Background Information**
- Qtern® is a fixed dose combination (FDC) of saxagliptin and dapagliflozin. Each tablet contains 5 mg saxagliptin and 10 mg dapagliflozin. The recommended dose is one tablet once daily.
- Qtern® is licensed in adults aged 18 years and older with type 2 diabetes mellitus:
  - to improve glycaemic control when metformin and/or sulphonylurea (SU) and one of the monocomponents of Qtern® do not provide adequate glycaemic control,
  - when already being treated with the free combination of dapagliflozin and saxagliptin.
Note concomitant add on has not been licensed for use.

**Assessment against Ethical Framework**

**Evidence of Clinical Effectiveness**

CV181168 - Randomised, double-blind, placebo-controlled, parallel-group, multicentre study to compare saxagliptin vs placebo added to dapagliflozin and metformin
- **Patients**: Patients with T2DM, ≥18 years with inadequate glycaemic control (HbA1c ≥8.0% and ≤11.5%) under current metformin therapy stable at ≥1500 mg for at least 8 weeks prior to screening.
- **Intervention and comparator**: At initial screening all patients received open-label dapagliflozin (10 mg/day) in addition to metformin for 16 weeks. Patients with inadequate glycaemic control (HbA1c 7–10.5%) (mean baseline HbA1c 7.9%) were then randomised to receive placebo (n=162) or saxagliptin 5 mg/day (n=153) in addition to background dapagliflozin and metformin for the 24 double-blind treatment period (total population n=315).
- **Primary Outcome**: There was a significantly greater reduction in HbA1c at 24 weeks with dapagliflozin add on (−0.51% [−5.6 mmol/mol]) vs. placebo (−0.16% [−1.7 mmol/mol]) (difference, −0.35% [95% CI −0.52% to −0.18%] and −3.8 [−5.7 to −2.0 mmol/mol], respectively p<0.0001).
- **Secondary Outcomes**: A larger proportion of patients achieved HbA1c <7% (53 mmol/mol) with saxagliptin add on (35.3%) vs. placebo add-on (23.1%) (difference 12.2%).

MB102129 - Randomised, double-blind, placebo-controlled, parallel-group, multicentre study to compare dapagliflozin vs placebo added to saxagliptin and metformin
- **Patients**: Patients with T2DM, ≥18 years with inadequate glycaemic control receiving treatment with stable metformin (stratum A) (screening HbA1c level 8.0–11.5% [64–102 mmol/mol]) or stable metformin and a DPP-4 inhibitor (stratum B) (HbA1c 7.5–10.5% [58–91 mmol/mol]) for ≥8 weeks
- **Intervention and comparator**: Patients received open-label saxagliptin 5 mg/day and metformin for 16 weeks (stratum A) or 8 weeks (stratum B) (saxagliptin replaced any DPP-4 inhibitor). Patients with inadequate glycaemic control (HbA1c 7.0–10.5% [53–91 mmol/mol]) (mean baseline HbA1c 8.2%) were randomised to receive placebo (n=160) or dapagliflozin 10 mg/day (n=160) added to a background of saxagliptin and metformin (total population n=320).
- **Primary Outcome**: There was a significantly greater reduction in HbA1c at 24 weeks with dapagliflozin add on (−0.82% [−9.0 mmol/mol]) vs. placebo (−0.10% [−1.1 mmol/mol]) (difference, −0.72% [95% CI −0.91% to −0.53%] and −7.9 [−9.9 to −5.8 mmol/mol], respectively p<0.0001).
- **Secondary Outcomes**: Significantly more patients achieved HbA1c <7% (53 mmol/mol) with dapagliflozin add on (38%) vs. placebo add-on (24.4%) (difference 25.5%, p<0.0001)

Following open label extension in both studies effects on Hba1c were sustained at week 52

**Limitations and Comments**
- Limited long term efficacy and safety data
- No data on patient orientated outcomes eg cardiovascular
- No comparisons with alternative triple therapy options recommended by NICE

This HMMC recommendation is based upon the evidence available at the time of publication. The recommendation will be reviewed upon request in the light of new evidence becoming available.
Safety
- The cautions, contra-indications, interactions & adverse-effects from the monocomponents apply to the FDC.
- The EPAR report included pooled data from 3 studies (the 2 studies above and a concomitant add on study of similar design):
  - There were no differences in hypoglycaemia, SAEs, related AEs or SAEs and no deaths occurred during the studies.
  - Incidence of subjects who discontinued study treatment due to an AE was low.
  - Adverse events of special interest: no differences between treatment groups, and there were no unexpected findings.
  - Female subjects experienced more AEs than males, especially UTIs & vulvovaginal mycotic infections.
  - Overall, the common AEs reported were generally consistent with the known safety profiles of saxagliptin or dapagliflozin. 3 most common AEs reported in the saxagliptin + dapagliflozin + metformin group were nasopharyngitis (3.7%), headache (3.5%) & UTI (3.5%); in the saxagliptin + metformin group were UTI (5.4%), influenza (4.5%) & headache (4.2%); in the dapagliflozin + metformin group were UTI (3.8%), influenza (3.2%) & nasopharyngitis & headache (2.9% each).

In conclusion: As expected, specific side effects related to the monocomponents, such as UTI for dapagliflozin & GI events for saxagliptin may occur when the two products are given together such as in a fixed dose combination, but in general the FDC was tolerated reasonably well. It is acknowledged that only a relatively small number of uncomplicated patients were tested.

### Cost of treatment and Cost Effectiveness

**Qtern® is currently the highest cost oral treatment for T2DM:** £49.56 x 28 - £646/year
- Costs are lower than if the combination of dapagliflozin & saxagliptin used separately – cost £889/year.

**Qtern® is lower cost than any combination of DPP4 inhibitor with SGLT2 inhibitor – cost £824-£911/year**
- Qtern® is lower cost than GLP-1 agonists but higher cost than insulin

**This combination with metformin is higher cost than alternative oral triple therapy regimes recommended by NICE but lower cost than triple therapy regimes with GLP-1 mimetic or if DPP4is or SGLT2is are combined with insulin.**

**No cost-effectiveness analysis available for this combination.**
- Cost effectiveness analysis was undertaken by NICE in the development of current guidelines for T2DM. Use of high cost combinations (DPP4i with SGLT2i and GLP1 mimetic with SGLT2i) which are not included in NICE recommendations are likely to increase costs for T2DM treatment. The cost-effectiveness of these combinations is uncertain.

### The needs of the population
- The needs of the population appear low as there is a range of alternative options approved by NICE.
- If this combination is indicated patients may prefer a FDC rather than taking separate monocomponents.
- There will be patients who will not be controlled on current triple therapy regimes recommended by NICE. Patients may prefer an alternative oral treatment combination rather than progressing to injectable therapy with GLP1 agonists or insulin.

### The needs of the community
- If this combination is used as part of a triple therapy regime in preference to current NICE approved oral triple therapy regimes then this would have a significant cost impact. The NICE costing report for canagliflozin estimates 2,000 patients for each CCG (ENHCCG and HVCCG) are receiving triple therapy. If 25% of these patients received Qtern® with metformin instead of current treatment this would increase costs by approximately £60k-£300k/year.
- If this combination is an additional option there may not be a requirement or a delayed requirement for progression to injectable higher cost GLP-1 agonists or insulin which may avoid costs.
- The current level of SGLT2i with DPP4i prescribing is uncertain.
- If Qtern®/ saxagliptin + dapagliflozin combination is recommended as an option, to realise the lower cost of Qtern® vs monocomponents then it would appear that 1st line choices would have to be saxagliptin and dapagliflozin.
- A FDC combination of empagliflozin with linagliptin is in development. It would appear likely that A FDC of canagliflozin with a DPP4i will be available in the future.

### Policy Drivers
- Current HMMC recommendations:
  - DPP4 inhibitor preferred choice is alogliptin: alogliptin is recommended within license for new patients requiring gliptin therapy, unless the patient has impaired renal function. In these circumstances, linagliptin is the agent of choice as no dosage adjustment is required. Advocating the use of Qtern® which does not contain the usual preferred choices is likely to cause confusion.

This HMMC recommendation is based upon the evidence available at the time of publication. The recommendation will be reviewed upon request in the light of new evidence becoming available.
All SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) are recommended as treatment options for restricted use in accordance with the relevant NICE TA recommendations. Feedback from some local specialists is that empagliflozin may be the preferred choice.

- Patients initiated on this fixed dose combination product who develop renal function decline would be required to change to two separate and different agents.
- The NICE TAs for SGLT2 inhibitors did not include recommendations for the combination with DPP4 inhibitors (including as FDC) (not considered)

Note the TA evaluated triple therapy including SGLT2i vs triple therapy including DPP4i is not a triple therapy combination including SGLT2i with DPP4i. No TAs in development reviewing this combination.

- The NICE Guidelines for T2DM did not include recommendations for the combination of SGLT2 with DPP4 inhibitors (including as FDC) (not considered)
- SMC: following an abbreviated submission: Qtern® in combination with metformin when the use of a sulphonylurea is inappropriate is accepted for restricted use for adults aged 18 years and older with type 2 diabetes mellitus.
- HVCCG treatment options algorithm for T2DM is based on the NICE guideline and does not include recommendations for triple therapy outside of NICE recommendations. It does not include recommendations for the combination of SGLT2 with DPP4 inhibitors or SGLT2 inhibitors with GLP1 agonists.
- No local CCGs appear to have considered Qtern® for use for T2DM.

**Equity**

- No impact anticipated

**Implementability**

- No issues identified

**References**

- HMMC recommendations (including choice): [DPP-4 Inhibitors (Gliptins) summary including choices](https://www.nhs.net/hmmc/)
- HMMC recommendations [Sodium-glucose cotransporter-2 inhibitor comparison table](https://www.nice.org.uk/guidance/ng28/o/Appendix F: Full Health Economics Report)
- Scottish Medicines Consortium (SMC) Advice (July 2017) [https://www.scottishmedicines.org.uk/SMC_Advice/Advice/1255_17_saxagliptin_dapagliflozin_fixed_dose_combination_Qtern®/saxagliptin_dapagliflozin_fixed_dose_combination_Qtern®](https://www.scottishmedicines.org.uk/SMC_Advice/Advice/1255_17_saxagliptin_dapagliflozin_fixed_dose_combination_Qtern®/saxagliptin_dapagliflozin_fixed_dose_combination_Qtern®)
- Dapagliflozin in combination therapy for treating type 2 diabetes (TA288) and [Dapagliflozin in triple therapy for treating type 2 diabetes (TA418)](https://www.nice.org.uk/guidance/ng28/evidence)
- Qtern® for the treatment of T2DM: Medicines evidence pack to support formulary and guidelines (Oct 2017)